NEW YORK (Reuters Health) Jun 12 –
Contrary to expectations, COPD patients given short-term, high-dose steroid treatment for exacerbations appear to be at greater risk of osteoporosis than those receiving daily therapy with oral glucocorticoids, according to Dutch researchers.
Lead investigator Dr. Emile F. Dubois of the University of Amsterdam, told Reuters Health that “osteoporosis is being observed more frequently in COPD patients who receive glucocorticoids as a treatment for exacerbation.” In an attempt to reduce such side effects, “these drugs are frequently given in short courses. This practice is generally assumed to be safe, since patients are only treated for a short period of time.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!